A novel chimeric dengue vaccine candidate composed of consensus envelope protein domain III fused to C-terminal-modified NS1 protein.

MLA

Huang, Hong-Jyun, et al. “A Novel Chimeric Dengue Vaccine Candidate Composed of Consensus Envelope Protein Domain III Fused to C-Terminal-Modified NS1 Protein.” Vaccine, vol. 40, no. 15, Apr. 2022, pp. 2299–310. EBSCOhost, https://doi.org/10.1016/j.vaccine.2022.02.070.

APA

Huang, H.-J., Yang, M., Chen, H.-W., Wang, S., Chang, C.-P., Ho, T.-S., Kao, Y.-S., Tien, S.-M., Lin, H.-H., Chang, P.-C., Lai, Y.-C., Hsiao, Y.-P., Liu, Y.-L., Chao, C.-H., Anderson, R., Yeh, T.-M., Lin, Y.-S., & Wan, S.-W. (2022). A novel chimeric dengue vaccine candidate composed of consensus envelope protein domain III fused to C-terminal-modified NS1 protein. Vaccine, 40(15), 2299–2310. https://doi.org/10.1016/j.vaccine.2022.02.070

Chicago

Huang, Hong-Jyun, Martyr Yang, Hsin-Wei Chen, Shuying Wang, Chih-Peng Chang, Tzong-Shiann Ho, Yu-San Kao, et al. 2022. “A Novel Chimeric Dengue Vaccine Candidate Composed of Consensus Envelope Protein Domain III Fused to C-Terminal-Modified NS1 Protein.” Vaccine 40 (15): 2299–2310. doi:10.1016/j.vaccine.2022.02.070.